Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA
Exelixis, Inc., Alameda, California, USA.
Oncologist. 2019 Nov;24(11):1497-1501. doi: 10.1634/theoncologist.2019-0316. Epub 2019 Aug 9.
Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. NCT01835158.
卡博替尼治疗与舒尼替尼相比，可延长国际转移性肾细胞癌数据库联盟（IMDC）标准定义的中高危晚期肾细胞癌（RCC）患者的无进展生存期（PFS），并提高客观缓解率（ORR），在 CABOSUN 试验（NCT01835158）中。在该试验中，157 名患者按 1:1 的比例随机分配接受卡博替尼或舒尼替尼治疗，按 IMDC 风险组和骨转移的存在进行分层。在此，通过独立放射学委员会（IRC）分析了根据基线特征亚组的 PFS 和 ORR。卡博替尼治疗与舒尼替尼相比，在包括 IMDC 风险组、骨转移、年龄和肿瘤负担等亚组中，均与改善的 PFS 和 ORR 相关。NCT01835158。
